Clinical Trial on Agitation in Alzheimer's Dementia
← catalyst calendarNCT05543681 · readout ≤ 12 d
Sponsored by IGC Pharma, LLC (industry) · IGC — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
164estimated
Sites
31
Countries
Canada, Colombia, Puerto Rico +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-10-11 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2022-09-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Alzheimer Disease
- Agitation,Psychomotor
- Care Giving Burden
- NPS
- Aggression
Interventions
- Drug: IGC-AD1-Active — also filed as Active
- Drug: IGC-AD1-Placebo — also filed as Placebo
Primary outcome
what the primary-completion date above is the date OFAgitation
measured Baseline to week six
Permalink · IGC's whole pipeline · Catalyst calendar · Every registered study · What changed